A61P 5/48
Drugs for disorders of the endocrine system: of the pancreatic hormones
Official title: of the pancreatic hormones
A61P5/48 (Drugs for disorders of the endocrine system: of the pancreatic hormones) appears on 2,822 US grants and 4,431 published applications in this corpus.
Search patents in A61P- Granted patents
- 2,822
- Published applications
- 4,431
- Assignees
- 1,408
- Inventors
- 7,624
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 6 | 0 |
| 1996 | 5 | 0 |
| 1997 | 6 | 0 |
| 1998 | 11 | 0 |
| 1999 | 25 | 0 |
| 2000 | 27 | 0 |
| 2001 | 63 | 26 |
| 2002 | 61 | 111 |
| 2003 | 68 | 123 |
| 2004 | 42 | 184 |
| 2005 | 54 | 188 |
| 2006 | 77 | 192 |
| 2007 | 72 | 226 |
| 2008 | 96 | 215 |
| 2009 | 107 | 313 |
| 2010 | 167 | 336 |
| 2011 | 159 | 293 |
| 2012 | 195 | 287 |
| 2013 | 239 | 226 |
| 2014 | 218 | 236 |
| 2015 | 199 | 226 |
| 2016 | 145 | 208 |
| 2017 | 178 | 187 |
| 2018 | 123 | 149 |
| 2019 | 125 | 156 |
| 2020 | 97 | 133 |
| 2021 | 81 | 101 |
| 2022 | 51 | 82 |
| 2023 | 35 | 60 |
| 2024 | 42 | 63 |
| 2025 | 32 | 65 |
| 2026 | 11 | 45 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Focal adhesion kinase inhibitor as a therapeutic agent in diabetes11 Aug 2026US 12,702,667 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Engineered lipase variants14 Jul 2026US 12,680,091 B2Societe des Produits Nestle S. A.
- Compositions comprising miR-690 and methods therefor16 Jun 2026US 12,653,783 B2The Regents of the University of California
- Method of increasing proliferation of pancreatic beta cells, treatment method, and composition19 May 2026US 12,630,803 B2Icahn School of Medicine at Mount Sinai
- Three-dimensional microporous scaffold device for cell culture12 May 2026US 12,623,003 B2The Regents of the University of Michigan
- Polymer-based therapeutics for inductive browning of fat8 Oct 2026US 2026/0306643 A1Purdue Research Foundation
- Use of composition containing candesartan or azilsartan10 Sep 2026US 2026/0263425 A1Gachon University of Industry-Academic Cooperation Foundation
- Combination of beta-2-adrenergic receptor agonists and glp-1 receptor agonists for use in treating hyperglycaemia3 Sep 2026US 2026/0256751 A1Atrogi AB
- Heterotrimer g-receptor agonist composition, and uses thereof27 Aug 2026US 2026/0248867 A1MOF Science, LLC
- AMPK Activator Containing 1,1-diethoxyethane as an Active Ingredient and Its Use20 Aug 2026US 2026/0240790 A1Lux Anima Co., Ltd.
Most cited
By later US patents
- Methods and compositions for pulmonary delivery of insulin246US 5,997,848 AInhale Therapeutic Systems · 1999
- Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals233US 6,303,661 B1Probiodrug AG · 2001
- Use of GLP-1 or analogs to abolish catabolic changes after surgery230US 6,006,753 AEli Lilly and Company · 1999
- Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same222US 5,359,030 AProtein Delivery, Inc. · 1994
- Therapeutic preparation for inhalation202US 5,518,998 AAstra AB · 1996